D. Tenen

Publications564
h-index109
Citations40,593
Highly Influential Citations1,627
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • S. Orkin
  • 873 Publications • 107,311 Citations
  • I. Weissman
  • 1,279 Publications • 164,486 Citations
  • L. Chai
  • 94 Publications • 4,576 Citations
  • K. Akashi
  • 843 Publications • 35,137 Citations
  • Publications
  • Influence
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.
TLDR
The case of a patient with EGFR-mutant, gefitinib-responsive, advanced non-small-cell lung cancer who had a relapse after two years of complete remission during treatment with gefItinib, where the DNA sequence of the EGFR gene in his tumor biopsy specimen at relapse revealed the presence of a second point mutation, resulting in threonine-to-methionine amino acid change at position 790 of EGFR.
Transcription factors in myeloid development: balancing differentiation with transformation
TLDR
Transcription factors have been shown to be key determinants in the orchestration of myeloid identity and differentiation fates, and therapies designed to restore defective transcription factor functions are an attractive option in the treatment ofMyeloid and other human cancers.
Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice.
TLDR
A model by which transcription factors can direct the differentiation of multipotential precursors through activation of expression of a specific growth factor receptor, allowing proliferation and differentiation in response to a specific extracellular signal is suggested.
Enhancement of hematopoietic stem cell repopulating capacity and self-renewal in the absence of the transcription factor C/EBP alpha.
Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak
In a study of 105 patients with cancer and 536 without, all with confirmed COVID-19, cancer was predictive of more severe disease, with stage IV cancer, hematologic cancer, and lung cancer being…
AML1–ETO downregulates the granulocytic differentiation factor C/EBPα in t(8;21) myeloid leukemia
TLDR
It is suggested that restoring C/EBPα expression will have therapeutic implications in RUNX1–CBF2T1-positive leukemias and Cebpa knockout mice exhibit an early block in maturation.
Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-α (C/EBPα), in acute myeloid leukemia
TLDR
This is the first report of CEBPA mutations in human neoplasia, and such mutations are likely to induce the differentiation block found in AML.
Disruption of differentiation in human cancer: AML shows the way
  • D. Tenen
  • Biology
    Nature Reviews Cancer
  • 1 February 2003
TLDR
Uncovering the underlying pathways will improve the diagnosis and treatment of acute myeloid leukaemia, and provide a working model for other types of human cancer, including solid tumours.
The order of expression of transcription factors directs hierarchical specification of hematopoietic lineages.
TLDR
It is proposed that the order of expression of key transcription factors is critical for their interplay to selectively drive lineage specification programs, by which stem cells could generate multiple lineage cells in a hierarchical manner.
PU.1 (Spi-1) and C/EBP alpha regulate the granulocyte colony-stimulating factor receptor promoter in myeloid cells.
TLDR
The results reinforce the importance of both PU.1 and C/EBP alpha in the expression of myeloid-specific genes and neutrophil development.
...
1
2
3
4
5
...